A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
Price : $35 *
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Biogen
- 06 Jul 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 08 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.